Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hypnion Inc.

This article was originally published in Start Up

Executive Summary

Hypnion Inc. aims to develop the next generation of drugs for the multi-billion dollar sleep market. It is taking marketed CNS drugs that have known sleep/wake side effects, then optimizing those effects to create safe, non-addictive patentable analogs.
Advertisement

Related Content

Somnus Therapeutics Inc.
Lilly Doubles Down on Insomnia with Hypnion Acquisition
Lilly Doubles Down on Insomnia with Hypnion Acquisition
Insomnia: Pharma Wakes Up to the Next Huge CNS Market
Insomnia: Pharma Wakes Up to the Next Huge CNS Market
The Shifting Sands of Sleep Apnea
The Shifting Sands of Sleep Apnea
The Infrastructure Dilemma
The Infrastructure Dilemma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel